If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
== Measurement == Follicle-stimulating hormone is typically measured in the early follicular phase of the menstrual cycle, typically day three to five, counted from last menstruation. At this time, the levels of estradiol (E2) and progesterone are at the lowest point of the menstrual cycle. FSH levels in this time is often called basal FSH levels, to distinguish from the increased levels when approaching ovulation. FSH is measured in international units (IU). For Human Urinary FSH, one IU is defined as the amount of FSH that has an activity corresponding to 0.11388 mg of pure Human Urinary FSH. For recombinant FSH, one IU corresponds to approximately 0.065 to 0.075 μg of a "fill-by-mass" product. The mean values for women before ovulation are around (3.8-8.8) IU/L. After ovulation these levels drop to between (1.8-5.1) IU/L. At the mid of the menstrual cycle it reaches its highest value, between (4.5-22.5) IU/L. During menopause, the values goes up even more, between (16.74-113.59) IU/L. For men, the mean values are around (1.5-12.4) IU/L.
== Repackaging process and stability data == The transient or definitive displacement of the solid oral form from the original atmosphere to enter a repackaging process, sometimes automated, is likely to play a primary role in the pharmaceutical controversy in some countries. However, the solid oral dose is to be repackaged in materials with defined quality. Considering these data, a review of the literature for determination of conditions for repackaged drug stability according to different international guidelines is presented by F Lagrange.
== Principle == Many organic molecules contain multiple functional groups that may react under similar conditions. Protecting groups are therefore introduced temporarily to prevent unwanted reactions during synthesis. In an orthogonal protecting group strategy, different protecting groups are chosen so that each responds to a specific set of reaction conditions. For example, one protecting group may be removed by acidic conditions, while another may be removed by basic conditions. Because the removal of one group does not affect the other, the two groups are considered orthogonal.
== History == Pregabalin was synthesized in 1990 as an anticonvulsant that was developed as a successor to the related gabapentin. It was first synthesized by medicinal chemist Richard Bruce Silverman at Northwestern University in Evanston, Illinois. During 1988 to 1990, Ryszard Andruszkiewicz, a visiting research fellow, synthesized a series of molecules requested by Silverman. Upon testing in mouse seizure models by collaborators at Parke-Davis Pharmaceuticals, one looked particularly promising. In vitro, it activated L-glutamic acid decarboxylase, an enzyme, but this later proved to be unimportant to prevention of seizures. Silverman had originally hoped that the enzyme would increase the production of the inhibitory neurotransmitter GABA and block convulsions. After extensive development studies and clinical trials by Parke-Davis the drug was approved in the European Union in 2004. The US received FDA approval for use in treating epilepsy, diabetic neuropathic pain, and postherpetic neuralgia in December 2004. Pregabalin then appeared on the US market under the brand name Lyrica in the fall of 2005. In 2017, the FDA approved pregabalin extended-release Lyrica CR for the management of neuropathic pain associated with diabetic peripheral neuropathy, and postherpetic neuralgia. However, unlike the immediate release formulation, Lyrica CR was not approved for the management of fibromyalgia or as add-on therapy for adults with partial onset seizures.
Sources: en.wikipedia.org
α-Methylphenylalanine (α-MePhe or AMPA) is an artificial amino acid and a phenethylamine and amphetamine derivative. It is the α-methylated analogue of phenylalanine, the precursor of the catecholamine neurotransmitters, and the amino acid analogue of amphetamine (α-methylphenethylamine), a psychostimulant and monoamine releasing agent. α-MePhe is a tyrosine hydroxylase inhibitor, thereby preventing the transformation of tyrosine into L-DOPA, and results in depletion of the catecholamine neurotransmitters. It is also an inhibitor of phenylalanine hydroxylase, and in conjunction with phenylalanine administration, induces hyperphenylalaninemia analogous to that in phenylketonuria in animals. The drug is known to produce metaraminol (3,β-dihydroxyamphetamine), a catecholamine releasing agent, as an active metabolite in animals, and this metabolite contributes to its effects. α-MePhe is a substrate of the L-type amino acid transporter 1 (LAT1), which transports it across the blood–brain barrier into the central nervous system.
The League adopted the argument that no one segment of any mandate's population was entitled to favourable treatment over another, and the terms under which the mandate had been granted made no provision for special obligation towards whites. It pointed out that there was little evidence of progress being made towards political self-determination. Just prior to World War II, South Africa and the League remained at an impasse over this dispute.
mitotic recombination Also somatic crossing over. The abnormal exchange of genetic material between homologous chromosomes during mitosis (as opposed to meiosis, where it occurs normally). Homologous recombination during mitosis is relatively uncommon; in the laboratory, it can be induced by exposing dividing cells to high-energy electromagnetic radiation such as X rays. As in meiosis, it can separate heterozygous alleles and thereby propagate potentially significant changes in zygosity to daughter cells, though unless it occurs very early in development this often has little or no phenotypic effect, since any phenotypic variance shown by mutant lineages arising in terminally differentiated cells is generally masked or compensated for by neighboring wild-type cells.
== Research == Polyphenols are a large, diverse group of compounds, which makes it challenging to determine their biological effects. They are not considered nutrients, as they do not contribute to growth, survival, or reproduction, nor do they provide dietary energy. Therefore, they do not have recommended daily intake levels, such as those for macronutrients and micronutrient (vitamins and minerals). In the United States, the Food and Drug Administration issued guidance to manufacturers that polyphenols cannot be mentioned on food labels as antioxidant nutrients unless physiological evidence exists to verify such a qualification and a Dietary Reference Intake value has been established – characteristics which have not been determined for polyphenols. In the European Union, two health claims were authorized between 2012 and 2015: 1) flavanols in cocoa solids at doses exceeding 200 mg per day may contribute to maintenance of vascular elasticity and normal blood flow; and 2) olive oil polyphenols (5 mg of hydroxytyrosol and its derivatives such as oleuropein complex and tyrosol) may "contribute to the protection of blood lipids from oxidative damage", if consumed daily. As of 2022, clinical trials that assessed the effect of polyphenol-rich diets on health biomarkers are limited, with results difficult to interpret due to the wide variation of intake values for both individual polyphenols and total polyphenols. Polyphenols were once considered as antioxidants, but this concept is obsolete.
=== 11 June === Russia claimed to have taken the villages of Synkivka, 120 kilometers east of Kharkiv, and Myasozharivka in Luhansk Oblast. The claim over the capture of Synkivka was not supported by war analysts like DeepStateMap.Live, which continued to depict Russian attack vectors to the north and east of the village, but no capture. A Ukrainian Switchblade, believed to be a 600 or improved model, struck a Russian Buk missile launcher in Sarabash, Donetsk Oblast. Ukraine formally established the Unmanned Systems Forces, a branch of the Ukrainian military presiding over the force's drone operations. The US State Department lifted its ban on providing weapons and training to the Azov Regiment after clearing them on charges of human rights abuses in a review. The New York Times reported that the Russian army was recruiting female prisoners to serve in Ukraine. During a press conference in Germany with President Zelenskyy, German Defence Minister Boris Pistorius announced that Germany and its allies had collected some 100 Patriot missiles for delivery. Pistorius further announced that Germany would also donate a third Patriot battery, IRIS-T missiles and more Gepard anti-aircraft guns in a package worth some five hundred million euros.
Sources: en.wikipedia.org
=== By U-Pb age discordance === Before applying detrital zircon ages, they should be evaluated and screened accordingly. In most cases, data are compared with U-Pb Concordia graphically. For a large dataset, however, data with high U-Pb age discordance (>10 – 30%) are filtered out numerically. The acceptable discordance level is often adjusted with the age of the detrital zircon since older population should experience higher chances of alteration and project higher discordance. (See Uranium–lead dating)
The grant was intended to support research into the interactions of hydrogen with palladium, nickel or platinum under extreme conditions. In March 2013 Graham K. Hubler, a nuclear physicist who worked for the Naval Research Laboratory for 40 years, was named director. One of the SKINR projects is to replicate a 1991 experiment in which a professor associated with the project, Mark Prelas, says bursts of millions of neutrons a second were recorded, which was stopped because "his research account had been frozen". He claims that the new experiment has already seen "neutron emissions at similar levels to the 1991 observation". In May 2016, the United States House Committee on Armed Services, in its report on the 2017 National Defense Authorization Act, directed the Secretary of Defense to "provide a briefing on the military utility of recent U.S. industrial base LENR advancements to the House Committee on Armed Services by September 22, 2016".
=== Notable cases === Dames & Moore v. Regan KindHearts for Charitable Humanitarian Development v. Geithner Genova Pipe v. Lutnick and Noem Learning Resources, Inc. v. Trump, and Trump v. V.O.S. Selections, Inc. Nintendo of America Inc. v. U.S. Department of the Treasury
The carpal bones and the transverse carpal ligament form the carpal tunnel. The median nerve passes through this space along with the flexor tendons. Increased compartmental pressure for any reason can squeeze the median nerve. Theoretically, increased pressure can interfere with normal intraneural blood flow, eventually causing a cascade of physiological changes in the nerve itself. There is a dose-respondent curve such that greater and longer periods of pressure are associated with greater nerve dysfunction. The symptoms and signs of carpal tunnel syndrome causes are hypertrophy of the synovial tissue surrounding the flexor tendons such as with rheumatoid arthritis. Prolonged pressure can lead to a cascade of physiological changes in neural tissue. First, the blood-nerve barrier breaks down (increased permeability of perineureum and endothelial cells of endoneural blood vessels). If the pressure continues, the nerves will start the process of demyelination under the area of compression. This will result in abnormal nerve conduction even when the pressure is relieved leading to persistent sensory symptoms until remyelination can occur. If the compression continues and is severe enough, axons may be injured and Wallerian degeneration will occur. At this point there may be weakness and muscle atrophy, depending on the extent of axon damage. The critical pressure above which the microcirculatory environment of a nerve becomes compromised depends on diastolic/systolic blood pressure.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.